17,261 trials
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Atopic Dermatitis
Primary: The Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response Which Improvement ≥ 2 From Baseline. — 9; 19; 2 Participants
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Prostate Cancer
Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only) — 0; 1 Participants
FIGO Stage III and IV Ovarian Cancer · FIGO Stage III and IV Fallopian Tube Cancer · FIGO Stage III Primary Peritoneal Cancer
Primary: Progression Free Survival — 50; 100 Percentage of PFS
Multiple Indications Cancer
Primary: Number of Participants Who Received Dasatinib Treatment — 1; 16 Participants
Relapsed Pediatric ALL · Relapsed Pediatric AML · Refractory Acute Myeloid Leukemia
Primary: Incidence of Low Dose Daunorubicin Feasbility as Assessed by Absolute Blast Count — 0; 1 Participants
Metastatic Breast Cancer
Primary: Sorafenib in Combination With Fixed Dose of of 2.5mg of Letrozole Maximum Tolerated Dose (MTD) — 400 milligrams twice daily
Mucocutaneous Lymph Node Syndrome · Kawasaki Disease
Primary: IVIG Refractory — 13; 22 Participants — p=.10
Molluscum Contagiosum
Primary: Proportion of Subjects Achieving Complete Clearance at Week 12 — 5; 16; 13; 18 Participants
Atherosclerosis
Primary: Progression of Subclinical Atherosclerosis — 4.77; 5.68 um/year — p=0.35
Colic
Primary: The Absolute Differences of I-GERQ-R Total Score at V3 (End of First Week of Treatment) Respect to the Baseline (V2). — -6.8; -7.6; -6.8 score on a scale
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
Intermediate Risk Prostate Cancer
Primary: Percentage of Participants With PSA at or Below 0.2 ng/ml — 79; 21 percentage of participants